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Nanomedicine, the integration of nanotechnological tools in medicine demonstrated promising potential to revolutionize the diagnosis
and treatment of various human health conditions. Nanoparticles (NPs) have shown much promise in diagnostics of cancer, especially since
they can accommodate targeting molecules on their surface, which search for specific tumor cell receptors upon injection into the blood
stream. This concentrates the NPs in the desired tumor location. Furthermore, such receptor-specific targeting may be exploited for detection
of potential metastases in an early stage. Some NPs, such as superparamagnetic iron oxide NPs (SPIONs), are also compatible with magnetic
resonance imaging (MRI), which makes their clinical translation and application rather easy and accessible for tumor imaging purposes.
Furthermore, multifunctional and/or theranostic NPs can be used for simultaneous imaging of cancer and drug delivery. In this review article,
we will specifically focus on the application of SPIONs in early detection and imaging of major cancer types.
From the Clinical Editor: Super-paramagnetic iron oxide nanoparticles (SPIONs) have been reported by many to be useful as an MRI
contrast agent in the detection of tumors. To further enhance the tumor imaging, SPIONs can be coupled with tumor targeting motifs. In this
article, the authors performed a comprehensive review on the current status of using targeted SPIONS in tumor detection and also the
potential hurdles to overcome.
© 2015 Elsevier Inc. All rights reserved.
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589,430 cancer deaths have been projected for 2015.1 A significant
improvement in cancer survival has been noted over the past three
decades for most cancer types. This notable and continuous
decrement in tumor fatality is related to advanced development in
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1549-9634/© 2015 Elsevier Inc. All rights reserved.decrease in overall prevalence of smoking.1 Early detection of
cancer, especially before cancer cells metastasize, is critical for
cancer diagnosis, because early stage cancers can be treated more
effectively. However, early-stage diagnosis has been difficult to
achieve in most cases since clinical symptoms tend to show up at
later stages. Therefore, minimally- and non-invasive methods for
early detection of cancer are urgently needed in the field. In this
regard,manySPION-based systems are under development formore
sensitive imaging and earlier detection of tumors. Since non-targeted
SPION species cannot readily differentiate cancer tissues from
normal tissues, second-generation SPIONs have been developed
which are equipped with targeting moieties that can recognizeide nanoparticles for early detection of cancer: Possibilities and challenges.
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Figure 1. The functions of different components in a SPION-based MRI contrast agent.
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subtype. This review provides a concise overview of second-genera-
tion targeted SPIONs in the detection and diagnosis of cancer. We
will also review the potential challenges associated with develop-
ment of such platforms and the opportunities that might be provided.SPIONs as contrast agents
Unlike other imaging modalities such as X-ray computed
tomography (CT) and positron emission tomography (PET), MRI is
preferred because it circumvents the need to use ionizing radiation
which can cause serious complications upon repeated scanning,
especially in children and young adults.2 MRI is a non-invasive
technique that provides even higher resolution than the former
methods.3 SPIONs are among the most favoredMRI contrast agents.
They are also used for drug/gene delivery,4 magnetic separation (e.g.,
in rapid DNA sequencing),5 magnetic hyperthermia therapy for
cancer,6 magnetotransfection,7 and stemcell tracking.8 This extensive
list of biomedical applications is not only attributed to their magnetic
properties and biocompatibility, but also to the capability of
synthesizing SPIONs in various shapes and sizes using several
techniques.A comprehensive reviewof SPION fabricationmethods is
beyond the scope of our discussion, but can be found elsewhere in the
literature.4,9,10 One of the key factors in the successful application of
SPIONs in clinical imaging and diagnostics is the availability of MRI
as a non-invasive and powerful system for tracking magnetic NPs.
When the size of magnetic materials reaches below a single
magnetic domain (corresponding to a core diameter of≤20 nm for
iron oxide) superparamagnetism occurs.9 By contrast with para-
magnetic materials, superparamagnetic NPs do not retain any
remnant magnetizationwhen the external magnetic field is removed,
which means that their magnetization can be switched on and off.
Due to their superparamagnetism and their strong effects on T2relaxation, SPIONs are the preferred NP agents for MRI contrast.11
T1 andT2MRI relaxation time constants are under the influenceof the
local microenvironment. Magnetic inhomogeneity is known as a
determining microenvironmental factor in MR imaging influencing
the T2 time constant. Thus, the high magnetic susceptibility of
SPIONs enables them to alter T2, T2*, or both, and as a consequence,
shortens the T2 and T2* relaxation. As a result, the regions in the
proximity of SPIONs can be identified by hypointense signals on the
MRimage and as such, agentswith higher relaxivity are preferred.The
T2 relaxivity for iron oxideNPs is usually at least 5-10 fold higher than
T1.12 Therefore, most iron oxide-based MRI contrast agents are
detected as a signal loss onT2-weightedMR images. The relaxivity of
iron oxide-based MRI contrast agents is largely dictated by
physiochemical properties such as size, composition, degree of
aggregation and surface coating.13 Increasing the diameter of these
particles leads to an increase in T2 relaxivities.14 Polymeric coatings
are also known to increase the T2 relaxivity.15 However, in
engineering NPs for in vivo applications, issues such as uptake by
the cells of the reticuloendothelial system (RES) and circulation time
should also be considered. For example, unmodified NPs can escape
internalization by theRES only if there are below100 nm in diameter;
otherwise, they need to be modified by e.g. PEGylation.16Tailoring SPIONs with targeting moieties
SPION-based systems are usually composed of an inorganic core
surrounded by a coating, which renders the particle biocompatible
and confers stability and/or solubility in aqueous solution.
Furthermore, the opsonization and circulation time of NPs can be
tuned by modulating their size and surface properties (see Figure 1).
Solid tumors usually have a leaky and damaged tumor
vasculature, as well as a poorly developed lymphatic drainage
system. NPs are believed to accumulate to a higher extent in this
Figure 2. The active targeting scheme for SPIONs and potential application of this strategy in MR imaging and drug delivery.
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called passive targeting using enhanced permeability and retention
(EPR effect).17 While such targeting strategies have proven to be
effective in certain cases – e.g. the uptake of dextran-coated SPIONs
was reported to be 10-fold higher in gliosarcoma compared to
healthy brain tissue in a rat model18 – passive targeting using naked
first generation SPIONs usually lacks the required specificity for
differentiating specific tumor types from normal tissues.
Therefore, second generation SPIONs are functionalized with
targeting moieties, such as monoclonal antibodies (mAbs), aptamers,
and smallmolecule ligands amongothers, allowing them to recognize
specific cellular receptors. Using this scheme, which is called active
targeting,19 a higher number of NPs can accumulate in the target
tissue and enhance the MRI contrast and imaging specificity. For
example, targeted imaging is employed for real-time tracking of
tumor angiogenesis and growth.20 In addition, active targeting limits
the off-target effects and minimizes the potential side-effects. An
overall scheme for active targeting is depicted in Figure 2.
An alternative targeting strategy that takes advantage of the
inherent magnetic properties of magnetic NPs including SPIONs, is
known as magnetic targeting. In this strategy, an external magnetic
field is applied to the desired location on the body in order to promote
the accumulation of injected magnetic NPs in that area. This allows,
for example, for targeting cancers close to the human skin.21 Passive
targeting of SPIONs has recently been reviewed.22 In the sections
below, active targeting of SPIONs in the diagnosis and detection of
cancer will be reviewed.
Common targeting ligands for imaging applications
Monoclonal antibodies are regarded as the most specific
moieties for targeting cancer cells. A list of mAbs and their
specific cellular antigens can be found in a review by Allen.23
However, there are a number of challenges associated with the
application of mAbs as SPION targeting agents. First and
foremost is the hydrodynamic size, often up to 20 nm,24 which
can increase the overall size of the conjugate and as such, reduce
NP extravasation and accumulation in the tumor site.25,26Furthermore, with increased size, the NPs' “stealth” character-
istics are compromised and more of them are taken up by cells of
the RES organs.27 Moreover, antibodies can be immunogenic to
an extent which cannot be easily predicted, given their
complexity and the genetic diversity of the individuals receiving
them.28 This issue is also very important, since a large number of
NPs must be injected for in vivo imaging. These challenges have
largely limited the application of mAbs as targeting ligands;
however, there are still a number of success stories out there,
examples of which will be discussed in the next sections.
To overcome the challenges associated with large antibodies,
antibody fragments have been considered as viable functional
targeting moieties. Such fragments include, but are not limited to,
Fab, ScFv-Fc, ScFv, (Fab′)2, minibodies, diabodies, nanobodies,
and peptides. Despite their advantages, fragments have rarely been
used for functionalization of SPIONs for imaging applications,29
likely due to the complexities associated with their production.
Aptamers are synthetic single-stranded DNA or RNA
oligomers used for specific targeting of biomolecules. Nowa-
days, aptamers are designed through the Systematic Evolution of
Ligands by EXponential enrichment (SELEX) method,30 a series
of sequential in vitro selection, purification and amplification
steps for characterization of a specific ligand with high binding
affinity for the desired antigen. Other more recent technologies
such as cell-SELEX allow for selection of aptamers that can
recognize specific cell lines.31 Aptamers have important
advantages compared to mAbs in that they are much smaller in
size and entail an easier manufacturing process.32 Moreover,
since they are smaller, a large number of distinct aptamers can be
accommodated on the surface of NPs, permitting multivalent
binding and synergistic affinity (up to 26-fold greater than the
intrinsic affinity of individual aptamers).33 Aptamers with very
high specificity have been engineered, with the ability to even
differentiate subtypes of non-small cell lung cancer.34 In one
such SELEX study after 15 rounds of enrichment, Li and
colleagues35 selected high affinity DNA aptamers that specifi-
cally bind to MDA-MB-231 breast cancer cells. Furthermore,
among this panel of aptamers (having a Kd, dissociation constant,
Figure 3. Versatile targeting ligands used in SPION-based imaging systems for specific detection of tumor cells. The ErbB2 aptamer sequence has been adapted
from Kim and Jeong.36 Concanavalin A structure has been derived from RCSB-PDB ID: 2UU8. Reproduced with permission.180
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exhibited a low Kd value (44 ± 8 nM) as well as outstanding
selectivity for MDA-MB-231 cell recognition. The truncated
version of the LXL-1 aptamer, LXL-1-A could distinguish the
breast cancer tissue against breast cancer tissue with metastasis in
76% of the cases. Similar studies of this type have been
conducted for selecting other cancer cell-specific aptamers – e.g.
against the extracellular domain of ErbB236 and hnRNP A137 for
breast cancer, as well as against epithelial cell adhesion molecule
(EpCAM)38 and integrins39 present in most solid tumors.
Lectins are another class of targeting ligands, which bind to
the glycoprotein and glycolipid moieties of glycans on the cell
membrane. Since glycans are central to a variety of cellular
activities, such as cell–cell communication, adhesion, differen-
tiation and development, their overexpression or aberrant
expression on the cell membrane is usually associated withcancer, either as a cause or consequence.40 As such, lectins, such
as wheat germ agglutinin (WGA), may be employed for targeting
of NPs for cancer imaging or therapy. Despite the extensive
applications of lectin-NP conjugates in investigating the glycan–
NP interactions,41 there is only a small number of studies using
lectin-functionalized NPs for imaging applications.
Cell-penetrating peptides are yet another class of targeting
moieties. The trans-activating transcriptional activator (TAT), the
first member of this class of molecules, was initially discovered in
human immunodeficiency virus 1 (HIV-1).42 This peptide sequence
was shown to be internalized by a panel of cell lines. Ever since,
these peptides have been employed for delivering variousmolecular
cargos into cells, usually via endocytosis. Since then, several
cell-penetrating peptides (including RGD) have been discovered
and extensively exploited for targeted therapy and imaging.
However, they usually lack specificity toward a specific cell type.
Table 1
A cursory comparison of different targeting moieties.
Targeting moiety Specificity Size Immunogenicity Production cost and complexity
Monoclonal antibodies Highly specific 150 kDa (monomeric IgG) Possible Very high
Antibody fragments and fusions Highly specific 25-140 kDa
(based on fragment structure)
Possible High-very high
Aptamers Highly specific 5-25 kDa Low to no Medium (reasonable at large
scale; roughly b10% of antibody)
Lectins Moderately specific 36 kDa (WGA dimer) and
104-112 kDa (Concanavalin A)
Possible Very high
Cell penetrating peptides Moderately specific Small molecule Possible but none reported Low
Other small molecule ligands
(e.g., folic acid and MTX)
Moderately specific Small molecule None expected Low
Figure 4. SPIONs can help detect cancer in 4 different stages: 1) detection of
receptors overexpressed on cancer cell surface in the tumor mass; 2) detection
of unusual angiogenesis in the tumor microenvironment; 3) detection of
circulating tumor cells and 4) detection of soluble tumor biomarkers.
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can also serve as SPION targeting ligands. The folate receptor
(FR) is a cell-surface receptor which functions in binding and
internalizing folate. Since folic acid is pivotal to cancer cell
proliferation, it is generally overexpressed in cancer cells43;
however, it can also be found in minute quantities on the apical
surfaces of epithelial cells in a number of normal tissues such as
kidney, thyroid, lung, and brain.44 This ligand is the one most
extensively used for drug delivery and imaging applications.
Another small-molecule ligand that is commonly used is
methotrexate (MTX). MTX is a chemotherapeutic drug which
specifically kills cancer cells overexpressing FR. A schemerepresenting all targeting moieties discussed herein is provided
in Figure 3 and the overall comparison of different targeting
moieties with regard to specificity, size, immunogenicity and
costs of production has been presented in Table 1.Cancer detection
Several non-targeted SPION-based contrast agents are
already available in the clinic for general imaging applications.
However, non-targeted SPIONs cannot efficiently accumulate in
the tumor site. Targeted delivery of SPIONs can potentially
facilitate their accumulation in the vicinity of specific cancer
cells and thus improve the sensitivity of MRI. Fabrication and
development of SPIONs for detection of specific cancer types
and metastases are feasible given the current rate of progress in
the field. Next-generation SPION-based MRI contrast agents
have been developed by coating the SPION core with suitable
materials and conjugating with tumor-specific targeting moieties.
These advances have facilitated the use of MRI for early
detection of cancer formation and monitoring of treatment
efficacy. Overall, SPIONs have been employed for cancer
detection using four general strategies: 1) detecting receptors
overexpressed on cancer cell surface in the tumor mass; 2)
detecting abnormal angiogenesis in the tumor microenviron-
ment; 3) detecting circulating tumor cells and 4) detecting
soluble tumor biomarkers (see Figure 4). In the sections below,
the progress in the development of targeted SPION-based MRI
contrast agents will be reviewed for major cancer types.
Liver cancer
The first clinical application of SPIONs was in imaging of
liver tumors.45 This detection strategy is based on the fact that
hepatic macrophages, or Kupffer cells, can readily internalize
SPIONs in normal hepatic tissue, while liver tumors are mostly
devoid of such macrophages. This distinction in macrophage-
specific uptake of SPIONs leads to negative enhancement on T2/
T2*-weighted MRI sequences in tumor lesions, facilitating
detection of liver tumors or metastases as small as 2-3 mm. The
first such SPIONs clinically used in Europe were coated with
dextran T10. Later, other SPIONs with different sizes and
coatings were introduced into the market. However, none of
these early products were targeted. More recent investigations
have been centered on targeted SPION products.
Figure 5. The octapod iron oxide NPs have larger effective valium compared
to spherical model with the same geometry. Reproduced with permission.48
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magnetic strength of iron oxide NPs can be as the cost effective
approach to improve the MR imaging.46,47 For example, the
saturation magnetization and T2 relaxivity of iron oxide NPs
enhanced after increasing the NP size. It is easier and more cost
effective to tune the physicochemical properties of NPs than NP
functionalization with specific targeting ligands. Recently, Zhao
et al,48 demonstrated that the morphology of iron oxide NPs
affects the MR imaging efficacy. They revealed that the octapod
iron oxide NPs show higher contrast in T2 imaging of liver
cancer compared to spherical model (with the same geometry).
The octapod NPs have higher effective volume compared to
spherical NPs when they are exposed to external magnetic field
(Figure 5). They were also shown to induce more inhomoge-
neous local magnetic field which in turn leads to contrast
enhancement. Indeed, the excellent potency of octapod NPs in
MR imaging is related to their unique morphology.
Other studies have focused on engineering targeted SPIONs.
Anti-α-fetoprotein and anti-glypican 3 antibodies can be used for
targeting of hepatocellular carcinoma. The carboxylated dex-
tran-coated ultrasmall SPIONs (USPIONs) conjugated with each
one of these antibodies were shown to perform as well as bare
USPIONs in shortening T1 and T2 relaxation.49 Transmission
electron microscopy (TEM) images demonstrated the specific
internalization of anti-glypican 3-USPION and anti-α-fetopro-
tein-USPION probes into HepG2 through the GPC3 or AFP
receptors, while none or only a few non-targeted USPIONs
gained entry into the cell cytoplasm.
Maeng and coworkers50 developed a polymeric NP,
composed of poly (ethylene oxide)-trimellitic anhydride chlor-
ide-folate, doxorubicin (DOX), and SPIONs for dual imaging
and delivery. The polymeric NPs were competitively internalized
in FR-expressing Hep3B and KB cells, which was shown by
reduction in NP uptake when cells were co-treated with FA. The
presence of stained vesicles within the tumor cells indicated that
NPs were internalized through FR-mediated endocytosis.
Subsequently, the efficacy of DOX-carrying NPs was tested in
rat and rabbit liver cancer models, and compared with free DOX
and a commercial liposomal DOX formulation, DOXIL®. The
new formulation was selective for FR-expressing tumors and
decreased the tumor volume two- and four-fold more than free
DOX and DOXIL®, respectively. Moreover, immunohistochem-
ical analyses showed that the expression of CD34 (a marker of
angiogenesis) and Ki-67 (a marker of cell proliferation) was
lower in the group treated with the folate-conjugated polymericNPs, and many apoptotic cells were shown to be present, as
assessed by the terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay. Furthermore, in comparison with
Resovist®, a commercially available MRI contrast agent, this
folate-conjugated polymeric NP showed higher MRI sensitivity,
even with its lower iron content (2.5 mg/mL vs. 27.9 mg/mL).
At the same Fe concentration, the MRI contrast enhancement
was higher with the folate-conjugated polymeric NPs than with
Resovist®, both in vitro and in vivo.
EpCAM has also been used as a marker for targeted selection
and detection of hepatocellular carcinoma cells. In a study by
Pilapong and coworkers,51 aminosilane-coated iron oxide NPs
were conjugated with DNA-based EpCAM aptamers (hydrody-
namic size b100 nm). TEM studies demonstrated that EpCAM-
conjugated NPs were highly internalized into HepG2 cells
through receptor-mediated endocytosis. The majority (96%) of
SPION-bearing EpCAM-positive HepG2 cells could be isolated
with magnetic-activated cell sorting (MACS) and could be
successfully detected using MR phantom imaging in vitro.
Prostate cancer
Similar to some other types of solid tumors, the cure rate of
prostate cancer is highly dependent on how early the disease is
detected. For several years, Cambidex, non-targeted ferumoxtran-
10 coated with dextran T10, was considered a success story as a
contrast agent for detection of prostate cancer metastases. This
USPION-based product was intended for use in differentiating
metastatic from non-metastatic lymph nodes in patients diagnosed
with prostate cancer with suspected lymph node involvement.
However, this experimental product failed to gain FDA approval
and its production was discontinued.52
Current research is focused on specific targeting of prostate
cancer cells. Prostate-specific membrane antigen (PSMA), a
100 kDa cell-surface glycoprotein, is a marker for prostate
cancer cells, and has relatively low expression in normal prostate
as well as in kidney, brain, and small intestine.53 PSMA is also
expressed by the vascular endothelium of all solid sarcomas and
carcinomas.54 The intracellular domain of PSMA is masked by
the cell membrane and remains invisible to anti-PSMA
antibodies in blood; therefore, binding agents against PSMA
should target its extracellular domain.55,56 Based on this fact,
Abdolahi et al conjugated SPIONs with J591 mAb, which
specifically recognizes and binds to the extracellular domain of
PSMA.57 J591 is among the most promising candidates for
targeting viable prostate cancer cells for both detection and
treatment.58 The purpose of their study was to enhance the
delivery of contrast agent to PSMA-expressing cells, thereby
enhancing contrast in those cells. The authors also fabricated
probes for PSMA-expressing lymph node carcinoma of the
prostate (LNCaP) cells, and demonstrated their high specificity
for these cells as compared with PSMA-negative DU145 cells.
Wang et al59 have developed a PEGylated, thermally
cross-linked SPION (TCL-SPION) that provides MRI contrast
combined with simultaneous DOX delivery to cancer cells.
TCL-SPIONs were functionalized with A10 aptamer, which
binds to the extracellular domain of PSMA, for targeting prostate
cancer (Figure 6). The differential internalization of aptamer-
Figure 6. TCL-SPION-A10 aptamer bioconjugate system with intercalated
DOX molecules. Redrawn with permission.59
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comparing the uptake of non-targeted and targeted TCL-SPIONs in
PSMA-expressing LNCaP cells and non-PSMA-expressing PC3
cells. Only the targeted TCL-SPIONs were internalized in LNCaP
cells 3 h after incubation and their accumulation increasedwith time.
Neither of the NPs could be internalized in PC3 cells. The change in
T1 and T2 relaxation times in LNCaP cells was not prominent upon
incubation with non-targeted TCL-SPIONs, while the targeted
SPIONs dramatically decreased T1 and T2 (T1: 1939 ± 116 to
263 ± 23 ms; T2: 104.2 ± 1.4 to 26.6 ± 0.4 ms). Furthermore, as
expected, the targeted SPIONs could not significantly decrease the
T1 and T2 in non-PSMA expressing PC3 cell lines. In a very similar
study,60 another group conjugated quantum dots onto the surface of
a nanocomposite composed of a 150 nm spherical polystyrene
matrix and embedded with 10 nm SPIONs. Furthermore, the
chemotherapeutic agent paclitaxel was loaded onto the surfaces of
the composites using a PLGA layer and the construct was further
functionalized with anti-PSMA antibody for specific detection of
LNCaP cells. The inclusion of quantum dots and SPIONs in the
same system makes it possible to perform bimodal imaging by
fluorescence and magnetic resonance, respectively.
Ghosh and coworkers61 developed new generation of carriers
which deliver large number of contrast agents per each cell
receptor. They arranged magnetic NPs on the M13 filamentous
virus which displayed a targeting peptide that specifically binds
to the SPARC glycoproteins. The magnetic NP-M13 showed
higher contrast efficacy in imaging of prostate cancer compared
to SPIONs directly bound to the targeting peptide (Figure 7). The
functionalization of carriers with targeting ligands can be a
promising approach to improve the targeted delivery of contrast
agents per cell. Using this strategy, the challenges of cell receptor
number/accessibility and overloading of targeting ligands were
tackled. This approach provides unique opportunities for
targeted imaging of different tumor cells, since it is possible to
display the desired targeting peptide using genetically engi-
neered M13.
Prostate stem cell antigen (PSCA) is another prostate tumor
biomarker target. PSCA expression is associated with tumor stage
and androgen-independence. As such, Gao et al62 synthesizedmultifunctional NPs composed of a poly(D,L-lactic-co-glycolic acid)
(PLGA), docetaxel, and SPIONs. To this core, a multilayer
poly(allylamine hydrochloride) shell was added, and then the
construct was further conjugated with two different-sized PEG
molecules, and a single-chain PSCA antibody. In vitro, the NPs
could sustain drug release over 764 h and caused significant
enhancement in MRI contrast in PC3M cells. Targeting with the
antibody enhanced NP internalization by 1.5-fold compared to
non-targeted NPs in PC3M cells after 2 h of incubation.
Furthermore, the targeted NPs specifically enhanced MRI contrast
in vivo in male nude mice bearing PC3M xenografts. When used to
treat mice, the NPs reversed tumor growth and significantly
increased the life span of mice. Since docetaxel is the main
chemotherapeutic for treatment of hormone-refractory prostate
cancer, these NPs have important implications in imaging and
drug delivery for this disease.
Brain tumors
The biodistribution and targeting efficacy of NPs are mainly
governed by the biological barriers. The NPs can easily obtain
access to the cancer cells/tissues directly exposed to the blood
stream while their journey to the pre-angiogenic and brain
tumors having no direct link to the blood is very difficult.63 Due
to blood brain barrier (BBB), there are many challenges
associated with the early detection and treatment of brain
tumor.64 In order to detect the pre-angiogenic and brain tumors
at the early stages, it is required to fabricate NPs capable of
penetrating the defense barriers. Cao et al,65 synthesized
magnetoferritin NPs capable of transport through the endothe-
lium, epithelium and BBB via clathrin-mediated endocytosis and
specifically detected the tumor cells which expressed the
transferrin receptor 1. Indeed, the magnetoferritin NPs can be a
promising candidate to overcome the challenges associated with
the NP biodistribution and targeted imaging of brain cancer.
Brain tumors are perhaps the most attractive targets for imaging
applications using USPIONs.66 In this regard, the efficacy of
non-targeted Ferumoxtran-10 and its derivative ferumoxytol contrast
agents has been already shown in MRI, e.g. in central nervous
system (CNS) lesions such as lymphoma, multiple sclerosis (MS),
acute disseminated encephalomyelitis, and vascular lesions.67-69
SPIONs can be conjugatedwithmoieties that are specific for various
CNS targets, including gliomas. Gliomas are among the most
common brain tumors.70 The surgical resection of these tumors
largely depends on delineating the tumor margins using an effective
imaging modality.71 For example, the glioma-specific chloride ion
channel is sensitive to chlorotoxin, a modified small peptide isolated
from scorpion Leiurus quinquestriatus venom.72 Chlorotoxin has
been employed for glioma targeting in a severe combined
immunodeficient (SCID)mousemodel bearing xenograft gliomas.73
In a study by Meng et al,74 SPIONs were conjugated with
chlorotoxin and the fluorescent dye, fluorescein isothiocyanate
(FITC), such that the targeting of human U251-MG and rat C6
glioma cells could be confirmed by MRI and the amount of NP
uptake could be measured by inductively-coupled plasma emission
spectroscopy. Confocal laser scanning microscopy was used for
optical imaging of functionalized NPs. The conjugation of
chlorotoxin to the NPs significantly enhanced preferential SPION
Figure 7. Left panel: tumor targeting with the NPs directly bound to the ligands; right panel: tumor targeting with large number of NPs arrayed on the genetically
engineered M13 displaying SPARC binding peptides. Redrawn with permission.61
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study also demonstrated that PEG-coated iron oxide NPs conjugated
with chlorotoxin can function as glioma-specific MRI contrast
agents.75 The NPs were coated with PEG to prolong serum half-life
in vivo by reducing protein adsorption and blocking non-specific
uptake by RES macrophages. Furthermore, the terminal functional
groups of PEG could be utilized for conjugation of ligands (e.g.,
chlorotoxin) and other potential therapeutic agents. The favored NP
localization in gliomas increased the MRI contrast in 9L cells and
athymic (nu/nu) mice bearing 9L gliosarcoma xenografts. The
internalization of NPs into the cytoplasm of 9L cells was validated
using TEM.
Shevtsov et al76 conjugated SPIONs with heat shock protein
Hsp70 for glioma imaging. The Hsp70-SPIONs enhanced the MRI
contrast in an orthotopic model of 9L glioma compared with the
non-targeted NPs. This high extent of contrast enhancement was
due to the accumulation of Hsp70-SPIONs in the gliomas, as shown
by histological analysis. There was a 40-fold greater uptake of
Hsp70-SPIONs in tumor than in normal brain tissue.
Transferrin receptor (TfR) is a transmembrane glycoprotein
involved in the uptake of the iron-chelating protein, transferrin (Tf).
Since iron is a fundamental element that plays major roles in
metabolism, DNA replication, and proliferation, highly proliferating
cells, such as cancer cells, usually have high iron demands.
Therefore, though TfR is expressed in normal tissues, it is usually
overexpressed in cancer cells.77 Since Tf is internalized through a
receptor-mediated pathway, it has been extensively used as a
targeting ligand in both imaging and drug delivery systems.
Furthermore, given the fact that the Tf internalization cycle takes
only 5 minutes to complete– corresponding to 20,000Tfmolecules/
cell/min78 – a large number of Tf-targeted SPIONs can be
internalized. SPIONs have been exploited for cell-sorting in bothbiomedical and industrial applications. For example, Durgadas et
al79 fabricated fluorescent superparamagnetic quantum clusters by
fusing near-infrared (NIR) fluorescent bovine serum albumin
(BSA)-stabilized gold clusters with dopamine-anchored SPIONs.
Subsequent addition of Tf to the resulting clusters lent targeting
capabilities to the hybrid clusters, as well as increased hemocompat-
ibility. The fabricated NPs could selectively eliminate C6 glioma
cells from blood and urine samples. Fluorescence could be detected
at the single-particle level, demonstrating the exquisite sensitivity of
the system. Therefore, circulating tumor cells could be detected in a
multimodal manner.
Jiang et al80 conjugated pH/temperature-sensitive magnetic
poly(N-isopropylacrylamide-co-acrylic acid) nanogels with
Cy5.5-labeled lactoferrin (hydrodynamic size of 95.5 ± 6.2 nm),
which is known to target glioma.81 Under physiological conditions
in blood and normal tissues, the nanogels were hydrophilic and
swollen, which increased their blood circulation time. In the lower
pH environment of tumor tissues (pH 6.8 vs. 7.4 in blood), the
nanogels became hydrophobic and shrank, which enhanced their
internalization by tumor cells (see Figure 8). These multifunc-
tional nanogels enabled in vivo MRI and ex vivo fluorescence
imaging with high sensitivity and specificity in a C6 glioma rat
model. 6 h post-injection, the targeted magnetic nanogels
generated a dramatic contrast enhancement in the tumor. There
was a gradual decrease in MR signal of 47-82% in individual
rats at 48 h post-injection.
Another protein ligand for imaging of brain tumors is
endothelial growth factor (EGF). In one study,82 SPIONs were
conjugated with recombinant human EGF. The targeted NPs
showed high internalization and no toxicity against C6 cells. An
orthotopic model of C6 gliomas was used to investigate NP
accumulation and biodistribution in tumors by MR imaging. NPs
Figure 8. The stimuli–response curves of magnetic nanogels. (A) Size
change of the nanogel in response to temperature at pH 6.8 and 7.4. (B) The
hydrophilicity/hydrophobicity of the nanogels in response to temperature at
pH 6.8 and 7.4. Reproduced with permission.80
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seen as hypo-intense regions on T2-weighted images.
Small-molecule ligands such as MTX have also been utilized
in targeting gliomas. For example, in one study,83 iron oxide
NPs modified with a PEG self-assembled monolayer (SAM)
were functionalized with MTX for simultaneous drug delivery
and MR imaging. The internalization of targeted NPs was
significantly higher than their non-targeted counterparts in 9L
cells. The NPs provided significant contrast enhancement in
cultured 9L cells and were more cytotoxic than free MTX. The
MTX antidote, leucovorin, reversed the cytotoxicity of the
conjugates and free MTX, showing that the observed cytotox-
icity is due to the bound MTX and not the conjugate. Since the
conjugates retained their crystal structure up to 144 h after
internalization, as shown by electron diffraction analysis, they
can be used for long-term imaging of tumor cells over the course
of treatment.Breast cancer
Several breast cancer cell markers such as FR, Her2/neu
receptor, Tf receptor (TfR), ErbB and integrins have been usedfor targeting of SPIONs to breast cancer tissue for imaging and
diagnostic applications.
In a study by Sun et al,84 SPIONs were initially coated with
covalently-bound bifunctional PEG and subsequently conjugat-
ed with folic acid. The NPs were shown to preferentially target
the FR-overexpressing HeLa cells and not the non-FR
expressing MG-63 osteosarcoma cells. The uptake of folic
acid-functionalized NPs in HeLa cells was 12-fold higher than
non-targeted NPs after 4 h of incubation. The functionalized NPs
caused a significant contrast enhancement in HeLa cells
compared to MG-63 cells in vitro. Furthermore, a competitive
inhibition assay in the presence of free folic acid demonstrated
the specificity of the nanoconjugate.
Kohler et al85 have developed iron oxide NPs modified with a
self-assembled monolayer (SAM) of (3-aminopropyl)trimethox-
ysilane and covalently bound with MTX, which can be used for
simultaneous MR imaging and drug delivery to breast cancer.
The SAM-modified NPs were conjugated with MTX through an
amide bond, such that MTX could be cleaved from the NPs in the
low pH environment of lysosomes after cellular uptake. In
human MCF-7 and HeLa cancer cell lines, MTX release was
monitored by UV absorbance (at 304 nm) under conditions that
simulated lysosomal pH and protease levels. Finally, cells
expressing the FR were shown to internalize the NP to a higher
extent than non-FR expressing cells.
Leuschner et al86 have shown that the specificity of
luteinizing hormone releasing hormone (LHRH) and chorionic
gonadotropin (CG)-bound SPIONs in human breast cancer cells
depends on the level of receptor expression in target cells as well
as the length of incubation. The neutral charge of these NPs
improves their cellular uptake and helps them to avoid uptake by
RES macrophages. The internalization of LHRH-conjugated
SPIONs was significantly higher than CG-conjugated SPIONs.
Furthermore, the accumulation of LHRH-conjugated SPIONs
was approximately 9 fold higher than that of non-targeted
SPIONs inside human breast cancer MDA-MB-435S.luc cells.
Ligand specificity was demonstrated by a decrease in intracel-
lular Fe content, as measured by Prussian blue staining, upon
co-incubation of the SPION conjugates with free ligand. Another
advantage of LHRH-conjugated SPIONs was poor incorporation
within macrophages. LHRH-conjugated SPIONs were mainly
localized in human breast cancer xenografts in a nude mouse
model, subcutaneously injected with 106 MDA-MB-435S.luc
cells in the interscapular region. On the other hand, non-targeted
SPIONs were mostly detected in the liver and not in the tumor. In
addition, the concentration of LHRH-conjugated SPIONs in the
lungs directly corresponded to the number of metastatic cells
present (77.8 pg Fe/metastatic cell), while non-targeted SPIONs
did not accumulate in the metastatic lesions of the lung in mice. As
such, these MRI contrast agents have potential applications in
detection ofmetastases in lymph nodes, bones, and peripheral organs.
Her2/Neu receptors are among the most specific markers in
targeting, staging, and treatment of breast cancer. Chen et al87
have fabricated SPIONs functionalized with dextran and
Herceptin. The dextran coating improved NP dispersibility in
solutions of various pH ranges and enhanced their saturation
magnetization (up to 80 emu/g). Moreover, the synthesized NPs
were minimally cytotoxic against a variety of cell lines. MR
Figure 9. T2*-weighted MR images of a mouse implanted with NIH3T6.7 cancer cells at 9.4 T along with their color maps at different time points after NP
injection. Tumor area has been shown with white dotted lines. Immediately after injection, a hypointense area (red dotted circle in the figure) appears at the
bottom of the tumor, which subsequently diffuses to the central and upper region of the tumor in a gradual manner. When the same MR images are subjected to
color mapping, more details of the MR signal changes are revealed, such that the progressive diffusion and targeting events of the NPs into the tumor tissue can
be seen as blue and green colors, corresponding to occupation of roughly 1/3, 1/2, and 2/3 of tumor tissues at 1, 4, and 12 h, respectively. Reproduced with
permission.89
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BT-474, SKBR-3, MDA-MB-231, and MCF-7, was greater in
cell lines with higher HER2/neu expression, validating the
targeting specificity. However, even cell lines with low HER2/
neu expression levels could be adequately detected. Upon
intravenous injection of these NPs into mice bearing breast tumor
allografts, a 45% drop in MR enhancement was seen in
T2-weighted MR images, which indicated the high accumulation
of NPs within the tumor site. A proportional enhancement in T2
MR images with respect to the number of receptors in different
cell lines has also been observed with streptavidin-conjugated
SPIONs functionalized with biotinylated mAb.88 In a similar
study, Huh and coworkers89 synthesized magnetic iron oxide
nanocrystals conjugated to Herceptin, which can selectively
target human cancer cells implanted in live mice in vivo. These
nanocrystal probes were further conjugated with fluorescent
dye-labeled antibodies, allowing them to be used both for in vitro
and ex vivo optical detection of cancer as well as for in vivo
MRI. Most importantly, this system allowed for detailed
monitoring of progressive cancer targeting at high magnetic
fields (9.4 T), revealing important information about the
complex vascular structures of the tumor tissue (Figure 9).
The effective treatment of stage 4 breast cancer relies on the
detection of small metastases. Kievit et al90 coated 8 nm SPIONs
with a chitosan/PEG copolymer, labeled them with a fluorescent
dye (Alexa Fluor 647 for in vivo or Oregon Green 488 for in
vitro detection), and further functionalized them with a mAb
against the Neu receptor (final hydrodynamic size of 40-47 nm).
As a negative control, SPIONs were conjugated with mouse IgG.
The Neu-functionalized NPs were highly internalized by
Neu-expressing mouse mammary carcinoma (MMC) cells, and
specificity to the Neu antigen was demonstrated by reversal of
the internalization in the presence of free Neu antibody. Not only
could the Neu-functionalized NPs target primary breast cancer
tumors, they were also capable of recognizing liver, lung, andbone marrow metastases in the transgenic mouse model of
metastatic breast cancer. This binding led to significant contrast
enhancement in MR images of both primary tumors and
micrometastases. Since non-targeted NPs failed to bind to
these metastases, it can be deduced that active targeting is
essential for delivery.
Kresse et al91 covalently coupled the human Tf to USPIONs
for in vivo imaging of SMT/2A tumor-bearing rats (rat mammary
carcinoma). With a half-life of 17 min in normal rats, the
conjugates could reduce the MRI signal of the tumor by 40%
(range 25-55%) 150 min after injection, and this signal reduction
could be maintained for at least 8 h. By comparison, the identical
parent USPIONs or those labeled with human serum albumin
could only induce a 10% reduction in tumor signal over time.
Integrins are heterodimeric transmembrane glycoproteins that
facilitate cell-matrix adhesion by acting as receptors for
molecules of the extracellular matrix (ECM). These interactions
underlie the induction of many signaling pathways that are
involved in cell-ECM communications. Among the different
combinations of α- and β-subunits (which give rise to 24 integrin
molecules), αvβ3 is of particular interest as an in vivo imaging
target, since it is known to be involved in the process of
angiogenesis, tumor development, and metastases, and can thus
be found on angiogenic vessels in malignant tumors. Indeed,
paramagnetic particles conjugated with LM609 mAb, which
targets αvβ3 expression, have been used for in vivo MRI
detection of angiogenesis.92 The majority of integrins, including
αvβ3, show a high binding affinity for arginine–glycine–aspartic
acid (RGD) peptides, which naturally occur in ligands specific
for integrin receptors. Consequently, RGD peptides have been
extensively used as targeting moieties for functionalization of
different NP systems, including SPIONs. Usually, due to higher
affinity and in vivo stability, the cyclic form of RGD peptides is
preferred over their linear counterparts.93 Furthermore, unlike
other tumor markers, due to the expression of αvβ3 integrin on
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tumor, RGD-targeted NPs can directly access these receptors
from the bloodstream, which reduces the need for NP
extravasation into the tumor microenvironment.94 In addition,
in certain cancer types, αvβ3 expression correlates with the
tumor grade.95 Thus, not only can integrins function as markers
for tumor imaging, but they also provide additional prognostic
information. SPIONs have also been conjugated with cRGD,
targeting integrins in a BT-20 breast tumor model.96 In this
study, the level of αvβ3 integrin expression, NP pharmacoki-
netics (mainly half-life), and tumor vascularization density
(related to the rate of NP escape from the vasculature) dictated
NP targeting efficiency. Due to uptake by integrin-expressing
cells, the targeted cRGD-conjugated SPIONs had a shorter
plasma half-life than non-targeted NPs (180 vs. 508 min).
However, even given their short half-life, the targeted SPIONs
could still target integrins on tumor cells. Since these NPs were
also functionalized with Cy5.5, αvβ3 integrin-expressing tumor
cells could also be visualized with fluorescence reflectance
imaging (FRI) and fluorescence molecular tomography (FMT) in
vivo. A similar study has shown the specific targeting of
αvβ3-rich glioblastoma and breast cancer, both in vitro and in
vivo, using c(RGDyK)-functionalized USPIONs.97 In another
similar approach to targeting αvβ3 for breast cancer imaging,
Yan and colleagues98 prepared PEG-modified and SPION-
encapsulated magnetoliposomes with biotin. In a guided 3-step
targeting approach, biotinylated anti-αvβ3 mAbs were intrave-
nously injected into mice bearing MDA-MB-435S breast tumors,
followed by injection of avidin/streptavidin and finally, injection
of the biotinylated magnetoliposomes. Fluorescence immuno-
histochemistry and Prussian blue staining were employed to
determine the specificity of αvβ3 targeting. The 3-step
pre-targeting approach enhanced the MRI contrast to a larger
extent compared with no targeting (7.0% of the tumor area vs.
2.0%), and the targeted magnetoliposomes were shown to
colocalize with neovasculature. In another study,99 iron oxide
NPs were coated with milk casein protein to generate NPs with
the final hydrodynamic size of ∼30 nm. Not only were the
fabricated NPs water soluble with acceptable colloidal stability
and biocompatibility, but they also had a transverse relaxivity
∼2.5-fold higher than that of identical core NPs with an
amphiphilic polymer coating. The NPs demonstrated strong
contrast enhancement in liver and spleen.
Gong et al100 fabricated dual-targeting micelles encapsulating
SPIONs from the amphiphilic block copolymer poly(ethylene
glycol)-poly(ɛ-caprolactone) (PEG-b-PCL) conjugated at the
distal ends of the PEG block with cRGD and ScFv-ErbB single
chain antibody. The efficiency of fabricated contrast agent was
assessed on an animal model produced by subcutaneous
injection of BT474 cells into the BALB/c-nu female nude mice
with a 1.5 T clinical MRI scanner. The dual-targeted magnetic
micelles delivered by tail vein injection decreased the T2 signal
intensity of the tumor in animals to a higher extent than single-
ligand targeted and non-targeted magnetic micelles.
Foy et al,101 designed an optical imaging based strategy to
assess the biodistribution and localization of magnetic NPs in
mice with xenograft breast cancer. To this end, the magnetic NPs
were modified by near infrared dyes and the circulation time,passive (in the absence of magnetic field), and active (in the
presence of magnetic field) targeting of NPs were tracked by
optical imaging. The authors demonstrated that tumor accumu-
lation and cancer detection efficacy of magnetic NPs exposed to
magnetic field were considerably higher than those with no
external magnetic field. Therefore, the combination of advanced
imaging with magnetically guided delivery of NPs may provide
exclusive opportunity to detect cancer cells in early stages.
The discovery and characterization of novel breast cancer
markers will usher in new targeting moieties. New markers, such
as low density lipoprotein receptor-related protein 5 (LRP5),102
low-density lipoprotein receptor 6 (LRP6),103 and others, may
prove to be applicable for imaging of breast cancer and its
metastases in the future.
Lung cancer
In cancer patients, treatment protocols and disease-manage-
ment strategies are largely based on the presence or absence of
metastases. Since lung is the organ most commonly invaded by
metastases,104 early detection of metastasis can significantly
contribute to improving the treatment and/or prognosis of
affected patients. Therefore, probes which can differentiate
metastatic cancer cells are highly desirable. Lung MRI is
challenging due to the low occupancy (20-25%) of the lung
volume by solid tissue (as most of the lung volume is comprised
of air). As a result, lung usually generates weak intrinsic MRI
signals. Furthermore, due to the presence of many air-tissue
interfaces in the lung, substantial field gradients are generated
which further weaken the MRI signal (T2* of 1 ms at 1.5 T in
humans105 and b0.8 ms at 2 T for small animals106). The advent
of hyperpolarized (HP) 3He and 129Xe MRI has paved the way
for high resolution imaging of the lung, since the high diffusivity
of these gases can negate most of the field gradients generated at
the alveolar walls. In this regard, Branca et al107 fabricated iron
oxide NPs functionalized with the LHRH targeting ligand, which
could then be visualized in vivo by high-resolution (HR) 3He
MRI. When tested in vivo in mice injected with breast
MDA-MB-231 adenocarcinoma or prostate cancer PC3 cells,
this system could efficiently detect pulmonary micrometastases
with molecular specificity 24-48 h after injection.
Jiang et al108 designed an RGD-conjugated 3-(aminopropyl)-
trimethoxysilane-modified USPION and used a 3.0 T clinical
MR scanner to non-invasively characterize the αvβ3 expression
pattern in animals with lung cancer. The two tumor models used,
A549 and 3LL lung cancer tumors, were shown to have different
αvβ3 expression patterns in MR images. For example in A549
tumors, αvβ3 expression was shown throughout the tumor, as
evidenced by a homogenous decrease of signal intensity.
Histological examinations of A549 tumor also revealed the
expression of αvβ3 in both the tumor vessel and tumor cells. By
contrast, in the 3LL tumor, the signal reduction was not
homogenous throughout the tumor, and the majority of signal
was distributed in the tumor periphery and some central regions.
In these tumors, SP staining demonstrated that αvβ3 is expressed
in the neovasculature. In a similar approach, Zhang et al109
fabricated a highly MR-sensitive magnetite nanocluster (MNC)
probe by clustering SPIONs (each 6.5 nm in size) with
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MNC with c(RGDyC) peptide (hydrodynamic size of 85 nm).
The engineered clusters were found to be highly sensitive (r2 =
464.94 s−1 mM−1) and specific for αvβ3-positive non-small cell
lung carcinoma cell lines A549 and H1299. Further studies in
athymic BALB/c nude mice implanted with H1299 cells
(4 × 106) under the left limb, demonstrated that both nascent
(35 ± 6.6 mm3) and large tumors (256 ± 22.3 mm3) can be
targeted by engineered clusters and imaged by MRI. Moreover,
the MR signal decrease was highly correlated with microvessel
density and αvβ3 expression levels at different growth stages, as
assessed by immunohistochemical studies.
Colorectal cancer
In the United States, colorectal cancer is the third most
prevalent type of cancer, accounting for 8% in men and 9% in
women of all cancer-related deaths in 2015.1 The development
of colorectal cancers is very slow and takes several years in most
cases. This process usually starts with the formation of a
non-cancerous benign polyp on the inner lining of the colon or
rectum. There are two main types of polyps, hyperplastic and
adenomatous, with the latter potentially resulting in cancer. Early
detection is necessary to identify polyps either before they
become cancerous or at the early stages, when they respond
better to therapy.110 Furthermore, since survival is significantly
better in non-metastatic colorectal cancer (90% 5-year survival),
early detection is of paramount importance.
Toma et al111 have conjugated Ferumoxide SPIONs with
mAb A7, which specifically interacts with the glycoprotein on
the surface of WiDr human colonic carcinoma cell line.112 The
binding activity of the conjugates was almost equal to the free
mAbs. The authors tested the accumulation of this NP system in
nude mice with xenograft tumors. The mAb A7-conjugated
SPIONs accumulated in tumors to a greater extent than control
SPIONs conjugated with non-specific IgGs. The SPIONs were
cleared from plasma in a linear rate. In T2-weighted MR images
of xenografts, signal intensity decreased at the tumor margin
upon injection of A7-conjugated SPIONs.
In certain cases, dual mode contrast agents can be employed
for coupling two imaging modalities for detection of cancer. He
et al 113 used bifunctional PEG-NHS ester disulfide
(NHS-PEG-S-S-PEG-NHS) linkers for conjugating Fe2O3@Au
core@shell NPs with three different lectins – concanavalin A
(ConA), Ricinus communis agglutinin I (RCA), WGA – for dual
T2-weighted MRI and CT imaging. The Fabricated system was
stable in different solutions (water, PBS and culture media) and
exerted no toxic effects against the cells. After 2 h of incubation
with SW620 cells, RCA- and WGA-bound NPs displayed strong
binding affinities, exceeding those of Con A-conjugated NPs.
This result confirmed that SW620 cells express high levels of
glycoconjugates containing Gal and N-acetyl-β-D-glucosaminoside
glycosyl complexes, as shown previously.114 Not only did the NPs
demonstrate the capability of dual-mode MR and CT phantom
imaging in vitro in SW620 cells, but they also successfully detected
subcutaneous colorectal tumors (SW620) in BALB/C nude mice, a
tumor model which is extensively used for mimicking the
intraperitoneal metastasis of colorectal cancers.The multifunctionality of NPs allows for simultaneous
therapy and imaging. In one such study, gold–iron oxide hybrid
NPs were functionalized with A33scFv.115 This antibody
fragment is known to target the A33 antigen, which is expressed
by the majority of primary and metastatic colorectal tumors.116
The A33scFv-targeted NPs were selectively internalized by
colorectal SW1222 xenograft tumors over non-A33-expressing
cells. Subsequently, these tumors underwent laser-assisted
photothermal treatment (808 nm, 5 W−1 cm−2) which adversely
affected more than 65% of A33-expressing SW1222 cells by
damaging the ECM and cytoplasmic acidophilia. Moreover, the
hybrid NPs could be selectively used to visualize subcutaneous
A33-expressing xenograft tumors by MRI.
In another study incorporating a dual drug delivery/MR
imaging probe, Zou et al117 conjugated PEG-coated SPIONs
(10 nm core) with HuCC49ΔCH2 antibody against TAG-72
antigen and 5-FAM fluorophore (final size of 44 nm) for
simultaneous MR and fluorescence imaging as well as
pH-dependent intracellular (lysosomal) drug release. In addition,
the anticancer agents DOX, azido-DOX, MI-219, and
17-DMAG were encapsulated within these NPs. Conjugation
with the antibody enhanced targeting to LS174T cells, as shown
by fluorescent imaging and confirmed by MR imaging and
Prussian blue staining. The targeted NPs had a T2 value of
55.5 ± 2.6 ms in LS174T cells compared to 117.3 ± 1.8 ms for
non-targeted NPs. Among the tested encapsulated drugs, all
except azido-DOX showed pH-dependent release. The
HuCC49ΔCH2-targeted SPIONs had a higher efficacy in
delivery of DOX to LS174T cells than non-specific IgG-targeted
SPIONs (IC50 of 1.44 μM vs. 0.44 μM).
Cervical cancer
Squamous cell carcinoma and adenocarcinoma are the two
most common types of cervical cancer. The majority of cervical
cancers are believed to arise from chronic human papillomavirus
(HPV) infections. In most cases, cervical cancer can be treated if
detected at early stages. Both cell penetrating peptides and small
ligands have been used for targeting of cervical cancer.
γ-Amino-proline-derived membrane translocating peptides
are relatively well-internalized into HeLa and COS-1 cells,118
are less toxic than TAT118 and more stable against protease
degradation owing to the γ-peptide skeleton. In a study by
Cavalli et al,119 SPIONs were conjugated with γ-amino-proline-
derived cell-penetrating peptide, which drastically increased the
internalization of targeted SPIONs into HeLa cells compared to the
analogous TAT–SPION conjugate. The internalization of NPs was
also confirmed by confocal microscopy. This high cellular uptake
decreased the T2 of labeled cells relative to control cells. Since the
peptide was also labeled with 5(6)-carboxyfluorescein (CF) dye,
these NPs combine fluorescent and magnetic properties in one
construct and can be used for multimodal imaging using both MRI
and confocal laser microscopy.
Sun and coworkers84 have developed PEG-coated SPIONs
targeted with folate for detection of HeLa cells overexpressing
FR. After 4 h incubation with HeLa cells, targeted NPs were
internalized 12-fold more than PEG- or dextran-coated NPs. The
preferential targeting of FR was shown in MR phantom imaging
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non-FR expressing osteosarcoma MG-63 cells. Furthermore, the
specificity of NPs to the FR was also compared in competitive
binding studies in the presence of free folic acid. The interchain
hydrogen bonding within PEG chains enhances the stability of
the coating.
In addition to its use in breast cancer (discussed earlier),
MTX85 has been used as a small-molecule targeting ligand for
MRI detection of HeLa cervical cancer cells. Another targeting
ligand used for detection of cervical cancer is hyaluronic acid,
which recognizes the CD44 receptor overexpressed on the
surface of cancer cells.120 Li et al121 modified hydrothermally
synthesized polyethylenimine (PEI)-stabilized Fe3O4 NPs with
FITC and hyaluronic acid (15-16 nm). The targeted NPs were
successfully taken up by CD44-overexpressing HeLa cells and
could also be used in vivo for detection of tumors in a HeLa
tumor-bearing mouse model.
SPIONs are sometimes coupled with other delivery agents to
increase the efficacy of drug delivery and imaging by combining
the advantages of both modalities. Liao et al122 employed
polymeric amphiphilic octadecyl-quaternized lysine-modified
chitosan (OQLCS) liposomes (PLs) conjugated with folate to
coat SPIONs (8-10 nm core). HeLa cells overexpressing FR
were shown to effectively internalize the folate-PLs-coated
SPIONs. The intracellular iron density was higher in cells
incubated with folate-PLs-coated SPIONs than those incubated
with folate-free PLs-coated SPIONs. Overall, the folate-PLs-
coated SPIONs also produced better T2-weighted MR images
than folate-free PLs-coated SPIONs.
Ovarian cancer
Ovarian cancer has received relatively less attention com-
pared to other types of cancer. One of the main markers for
ovarian cancer is the ovarian cancer-specific transmembrane
glycoprotein antigen, MUC1, which can be targeted by C595
antibody.123 Since the C595 mAb has anticancer activity, it can
have dual functions in both targeting and treating tumors.
SPIONs were thus conjugated with C595 mAb to produce
contrast agents for detection of ovarian cancer.124 The nanop-
robe reduced the signal intensity in MUC1-expressing OVCAR3
cells by 95%, compared with their non-targeted counterparts.
Moreover, the affinity of NPs for OVCAR3 cells was 5 times
higher than that of non-targeted NPs. C595-conjugated SPIONs
accumulated twice as much in the tumor site than in other organs.
While the reduction in signal intensity was 56% for C595-con-
jugated SPIONs, it was only 10% for non-targeted SPIONs.
Moreover, the NPs exerted selective toxicity against ovarian
cancer in vivo. The main disadvantage of these NPs was the
dramatic uptake by RES 24 h after injection; however, in special
cases, this feature can also be suitable for detection of liver and
spleen tumors.
Affibodies are antibody-mimetic molecules that can bind to a
large number of target proteins at the same time. In a study by
Gao et al125 Her2 affibodies were used to label maleimide-
functionalized NIR quantum dots (a core of 5 nm with an
emission wavelength of ~800 nm) or iron oxide NPs (core of
15 nm). Her2 is overexpressed in a number of cancers such asbreast, ovarian, lung, and gastric cancers. These conjugates were
then shown to be highly specific for Her2-expressing ovarian
SKOV3 cells and tumors. While the targeted quantum dots could
be used for fluorescent imaging of SKOV3 tumors in vivo and ex
vivo 4 h post-injection, treatment of cells in vitro with
affibody-labeled NPs produced significant cellular MRI contrast
compared to the identical cells treated with untargeted PEG-
coated iron oxide NPs. However, only a slight decrease in MRI
signal was observed upon MR imaging of SKOV3 tumor in vivo,
which was attributed to the low tumor uptake of affibody-labeled
iron oxide NPs or the low sensitivity of MRI.
Other potentially interesting molecular targets that can be
explored for imaging and early detection of ovarian cancer include
CD276,126 CD24, HE4, CD9, GA733-2 as well as cytokeratins 7, 8,
18, and 19.127
Other studies
Suwa et al128 coated SPIONs (13.2 ± 1.9 nm) with mAbs
directed against EGFR. EGFR is often over-expressed in esophageal
squamous cell carcinoma. The conjugated mAbs retained their
bioactivity after binding to the NP surface. The contrast enhance-
ment in T2 images was shown in the EGFR-expressing cell line TE8
compared to the non-EGFR-expressing cell line H69. The
subsequent in vivo studies in athymic rats bearing TE8 or H69
tumors also confirmed the EGFR-specific MRI contrast specificity.
The magnetic NPs were found to localize to the lysosomes upon
internalization, as shown by electron microscopy studies.
Carbohydrates can also be used for detection of lectin
receptors present on the surface of cancer cells. In one study,129
the authors used carbohydrates to synthesize glyco-NPs for
detection of cancer cells. Furthermore, they intended to
quantitatively assess the carbohydrate binding signature of
cancer cells. The authors used an array of magnetic NPs, each
functionalized with a specific sugar (Figure 10), and showed that
the NP array can differentiate malignant from normal cells,
closely related isogenic tumor cells, and cells with different
metastatic potential based on the unique lectin profile of the
different cells (Figure 11). Detection was based on the different
MRI signatures of the glycoconjugates.
This study also has implications in characterizing the
“glycocode” of different cancer cells, contributing to the overall
understanding of carbohydrates in cancer. Biological informa-
tion is encoded and stored within the varied structures of
cell-surface carbohydrates, which are involved in cell differen-
tiation, migration to specific tissues, cell adhesion, microbial
pathogenesis, and recognition by the immune system.130 In other
words, the glycocode can be the key to devising new diagnostic
and therapeutic modalities.
In an effort to detect leukemia cells in blood samples, Herr
et al131 developed a system composed of two NPs for collection
and subsequent sensing of these cells. For this purpose,
SPIONs were conjugated with an aptamer selected against
CCRF-CEM acute leukemia cells. Aptamer-modified magnetic
NPs were used for extraction of target cells, while fluorescent
NPs conjugated with the same aptamer were used for sensitive
detection of cells, such that even single-aptamer binding events
could be sensed.
Figure 10. The synthesis of carbohydrate-functionalized magnetic NPs. Reproduced with permission.129
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In any type of cancers, the minority of cancerous cells can leave
the cancer site, get into the circulation (so called “circulating tumor
cells”) and find a new site to settle down. This phenomenon can lead
to the formation of additional cancerous sites (i.e.,metastasis).As the
number of circulating tumor cells are rare in the first stage of
metastasis, early detection and analysis of these circulating cells in
clinic are of crucial importance. Recent reports demonstrated
promising results in use of various types of NPs (more specifically
magnetic NPs) for detection of circulating tumor cells. These reports
were completely reviewed by Bhana et al.132
Due to the similarity between normal and metastatic lymph
nodes, devising non-invasive methods for detection of metastatic
lymph nodes is a challenging task. To design SPIONs which
could be specifically internalized by immune cells, such as
macrophages and dendritic cells within lymph nodes, Vu-Quang
et al133 coated SPIONs with mannan polysaccharide (hydrody-
namic size of 46.2 ± 1.9 nm). Having a high D-mannose content,
mannan can bind mannose receptors on activated macrophages
as well as dendritic cells. Mannan-coated SPIONs were
significantly internalized by freshly-isolated peritoneal macro-
phages, as confirmed by Prussian blue and fluorescence staining,
which led to a significant improvement in contrast enhancement
upon MR phantom imaging 2 h post-treatment. When adminis-
tered to mice, these conjugates decreased the relative signal
intensity between popliteal lymph nodes and muscles at 1 h
post-injection and for up to 24 h.
In another study, a metastatic lymph node model was created
in BALB/c mice with subcutaneous injection of 107 malignant
4T1 breast cancer cells. Mannan-coated SPIONs could differen-
tiate normal from metastatic lymph nodes. It was hypothesized
that metastatic lymph nodes do not possess antigen presenting
cell-related functions and do not internalize mannan-coated
SPIONs to the extent that normal lymph nodes do. In normal
lymph nodes, there was a uniform reduction in signal intensitythroughout the whole region; whereas in metastatic lymph nodes,
the MR signal intensity was almost unchanged after administra-
tion of contrast agent. In another study,134 TCL SPIONs were
employed for MRI detection of lymph node metastasis in
C57BL/6 mice subcutaneously injected with B16F1 human
melanoma cells. In the majority of the nodes, the enhancement
pattern was consistent with the pathology. In another approach,
Vu-Quang et al135 synthesized SPIONs (15.7 ± 6.3 nm core)
functionalized with β-glucan, which can activate macrophages
by binding to (1,3)-β-D-glucan receptor or Dectin-1 receptor.
These SPIONs could target macrophages surrounding the
metastatic regions of the liver. Upon MR imaging in the
metastatic mouse liver model (created by injection of CT-26
colorectal carcinoma cells into a hemi-spleen), the preferential
uptake of targeted SPIONs within the metastases differentiated
them from the tumor cells, which did not internalize these NPs.
In order to detect the metastatic cells, Peiris et al,136 designed
chain shaped iron oxide NPs consisting of four iron oxide
nanosphere connected to each other in aligned direction. The
chain shaped iron oxide NPs were functionalized by cyclic
tripeptide arginine, glycine, glycine, aspartic acid that specifi-
cally attach to αvβ3 integrin. As the αvβ3 integrin is required for
metastatic site transition, its presence on the surface of cells can
be as used as potential diagnostic sign of metastasis cells.
Because of their multisite attachment on the αvβ3 integrin, the
chain shaped nanospheres showed high targeting and imaging
efficacy for detection of metastatic cell in animals with liver,
lung and breast cancer.The importance of developing animal models for testing
targeted contrast agents
Developing in vivo models for preclinical studies prior to
testing novel contrast agents and imaging platforms on humans is
essential, especially in cancers for which a suitable animal model
Figure 11. (A) Percentage change in T2 relaxation time after incubation of different magnetic (n = 6) NPs (20 μg/mL) with the 10 cell lines in the study (105
cells/mL). (B) Percentage change in T2 relaxation time after incubation of magnetic NPs (20 μg/mL) with 10 cell lines at the density of 106 cells/mL. The
significant difference in binding to different magnetic NPs led to the differentiation of these cell lines from each other. Reproduced with permission.129
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establish animal models for certain tumor types or their
metastases. For example, Ocak et al137 developed an FR-positive
murine ovarian cancer cell line, which could induce widespread
intraperitoneal tumors in immunocompetent mice within
4-8 weeks after implantation. The authors monitored the process
of tumor development using various imaging modalities,
including PET/CT in combination with a PET FR-targeting
reporter and fluorescence molecular tomography (FMT) in
combination with a commercial FR-targeting reporter.
Selective and specific detection of early prostate cancer
metastases to bone is a challenging task for current clinical imaging
techniques. In a similar effort as above, Sroka et al138 developed and
established a reproducible bonemetastasis xenograftmodel, and also
found cell-surface receptors that could function as molecular
imaging candidates for metastatic prostate cancer. For this purpose,
bone-trophic human prostate cells (PC-3B1) were injected intra-
cardially into SCID mice. Potential skeletal metastases were
investigated. The cells were found to maintain their bone-homing
phenotype for a relatively long time in culture and in vivo 3 weeks
after intra-cardiac injection. PC-3 and PC-3B1 cells were subjected
to transcriptomic profiling using a cancer-specific microarray.
Among the 55 upregulated genes (≥1.5 fold upregulation) inPC-3B1 cells, onlyAXL,CDH11,CD34, andMETweremembrane
receptors expressed in human tumors. These proteins can be
potentially used for targeting of bone metastasis associated with
prostate cancer.Protein corona
The “protein corona” is the layer (or composed of several
layers) of proteins and other types of biomolecules that
immediately covers the surface of NPs upon entry into a
biological fluid, such as plasma.139-141 This is due to their high
surface to volume ratio which confers a very active surface
chemistry to the particles. It has been shown in several studies
that the process of corona formation is very dynamic and
competitive. The evolution of protein corona starts with rapid
adsorption of low-affinity high-abundance proteins, some of
which are later exchanged with proteins of higher affinity and
lower abundance.142
The composition of proteins in the corona is largely dictated
by NP size and surface chemistry,143 crystallinity144 and
hydrophobicity145 as well as other parameters such as plasma
concentration146 and temperature.147,148 It is now being
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can also change the plasma composition which mirror significant
variation in structures of protein corona (i.e., amount, type, and
conformation of the associated proteins in the corona
composition).149-152 For example, it was demonstrated that the
cellular response (e.g., cellular toxicity, apoptosis, uptake,
reactive oxygen species production, lipid peroxidation and
nitrogen oxide levels) to the exact type of graphene oxide
nanosheets, but with coronas from different patients (including
hypofibrinogenemia, blood cancer, thalassemia major, thalassemia
minor, rheumatism, fauvism, hypercholesterolemia, diabetes), was
considerably different.149 The key message of this patient specific
protein corona is that specific design should be considered for NPs,
which are intended to be used in patients with different diseases, to
get safe and efficient targeting efficacy.
Complications of protein corona for delivery systems and MRI
contrast agents
As protein corona is the first contact point of an NP with the
cells and other biological species, the decoration of corona can
have a significant impact on the interactions of NPs with
biological systems. The proteins with highest affinity or the so
called hard corona mainly mediate the interaction of a given NP
with biological components.153
As such, the corona decoration can interfere with the
engineered functions of NPs. The protein corona has been
shown to offset the targeting capability of functional ligands
conjugated to NPs by up to 96%.154,155 This shows that majority
of successful in vitro nanoparticulate systems may have very low
in vivo efficacies. In addition, these NPs which are mainly used
for target-specific applications could be internalized by other
sites (as results of mis-targeting), such as brain tissue, and cause
severe unwanted cytotoxicity.156 In order to overcome this issue,
one should be able to control the decoration of protein corona
(mainly by adjusting physicochemical properties of NPs) or use
proper coatings that inhibit protein absorption to the surface of
NPs (e.g., zwitterionic coatings).157
Besides mis-targeting, adsorption of proteins has the
capability to largely change the relaxivity of contrast agents in
MR imaging. Amiri et al158 evaluated the effects of protein
adsorption from 10% v/v FBS on the magnetic properties of NPs
and their MRI contrast efficiency. For this purpose, two series of
SPIONs were synthesized, which differed in thickness and
functional groups (i.e., surface charges) of the dextran surface
coating. These different physiochemical characteristics resulted
in the generation of dissimilar protein coronas. Only plain NPs
retained their original relaxivity in the presence of protein
corona. The relaxivity of negatively charged SPIONs mildly
increased upon introduction into biological fluid and formation
of protein corona, while that of positively charged SPIONs
considerably reduced in the same conditions. In vitro MRI
experiments also confirmed the relaxometry findings. Therefore,
the protein corona is an additional criterion that must be taken
into account in the NP engineering process for in vivo imaging
and delivery applications.
Apart from influencing the drug delivery and MRI efficiency,
there are a couple of other concerns that are importantconsiderations for NP engineering, though they might not be
of immediate relevance to targeting. NPs can induce conforma-
tional changes in the proteins they come in contact with. For
example, gold NPs have been shown to induce reversible
conformational changes in both secondary and tertiary structures
of BSA.159 Furthermore, Mahmoudi et al160 have reported that
the interaction of SPIONs with iron-saturated human transferrin
can irreversibly open its compact conformation. NP-induced
protein denaturation and unfolding can lead to protein aggrega-
tion and/or presentation of new epitopes, which can hypothet-
ically cause conditions such as amyloidosis161 or immunological
reactions162 and inflammation.161
Rational engineering of NP surface can help reduce the
denaturation of interacting proteins. For example, while anionic
NPs inhibit the enzymatic activity of α-chymotrypsin by
denaturing its secondary structure,163 functionalizing NPs with
oligo(ethylene glycol) (OEG) significantly reduces α-chymo-
trypsin denaturation.164 Indeed, the activity of enzyme can be
specifically modulated by NPs, since chymotrypsin interaction
with the anionic NPs increased the catalytic activity of the
enzyme for cationic substrates by 3 fold, while the activity was
reduced for neutral and anionic substrates by 50 and 95%,
respectively.163 Interestingly, 2-(10-mercaptodecyl)malonic
acid-functionalized gold NPs have been shown to facilitate the
refolding of thermally denatured cationic proteins such as
chymotrypsin, papain and lysozyme.165
Therefore, in the future challenge called “safety by design”,
the ultimate purpose will be to tailor the various physiochem-
ical properties of a given NP such that the protein NP
interactions can be controlled and/or at least predicted to
some extent.
Potential advantages of protein corona
On the other hand, predictable enrichment of specific proteins
can come in handy in targeting of cells and tissues in delivery
and imaging applications. For example, albumin and apolipo-
protein adsorption leads to higher NP circulation times in
plasma,166 while opsonins such as fibrinogen, immunoglobulins
and complement proteins promote NP phagocytosis by cells of
the RES.167 Fibrinogen can promote the recognition of foreign
entities by monocytes, macrophages, and neutrophils, for
example through binding to CD11/CD18 on phagocytes.168,169
As another example, the cellular uptake of magnetite NPs by
macrophages was higher when lung surfactant protein A
adsorbed on their surface in comparison with NPs precoated
with BSA.170 The NPs harboring opsonin proteins in their
corona can potentially be promising candidates for delivery and
imaging in the RES. For a number of similar examples on the
effect of adsorbed proteins on targeting and cellular uptake,
please refer to this book chapter.171
Furthermore, the formation of protein corona is an inherent
physiological strategy to deal with the toxicity of foreign
substances. There are an increasing number of papers showing
that the protein corona reduces the toxicity of NPs in biological
systems. For instance, such mitigation of cytotoxicity has been
noted with silica and polystyrene NPs172 as well as graphene
oxide.173
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Provided the fact that protein corona formation is an
inevitable phenomenon in vivo, three paradigms have been
proposed in the delivery context.171 In the first modality, NPs
can be rendered non-fouling to circumvent the formation of
protein corona.157 In this approach, NPs are usually coated with
hydrophilic polymers, such as PEG174 or are functionalized with
zwitterionic groups such as amino acids and polybetaines. In one
such study, a number of zwitterionic gold NPs were produced
which could resist the adsorption of serum proteins in moderate
concentrations, and did not develop a hard corona at physiolog-
ical serum levels.157
In the second approach, some groups have actually started to
exploit the protein corona for drug loading and release. For
example in one study,175 both negatively charged oligonucleo-
tides and positively charged doxorubicin were loaded in the
protein corona of cetyltrimethylammonium bromide (CTAB)-
coated gold nanorods. The holding capacity of protein corona on
the nanorods was significantly higher than the covalent
conjugation of therapeutics on NP surfaces. As the temperature
has crucial effect on the protein corona composition,147,176 the
release of cargo could be changed by photo-induced plasmonic
heating of gold nanorods.
In the third approach, the formed protein corona itself can be
actively employed for lending targeting capabilities to the
delivery system. For materialization of such a strategy, the
composition of protein corona on the surface of specific NPs
with fully characterized surface chemistry must be thoroughly
determined, differentiating the proteins with highest abundance
or highest affinity on NP surface.171 In this regard, for example,
NPs with a corona enriched in transferrin, can be used for
targeting of transferrin over-expressing cells such as BT20,
MCF7, BT549, and HBL100.177 Similarly, most hydrophobic
NPs have been shown to enrich apolipoprotein A-I in their
corona, and they can be potentially used for drug delivery to
neurons, as apolipoprotein A-I interacts with low density
lipoprotein (LDL) and scavenger receptors in the brain capillary
endothelial cells.178 It is also noteworthy that scavenger
receptors are overexpressed in PC3 prostate carcinoma cell line
as well as in the liver and steroidogenic glands, intestine, and
placenta, and in cells such as macrophages and endothelial
cells.179 Progressive increase in our understanding of NP-protein
interactions will eventually help us overcome the challenges and
design futuristic highly specific and characterized NP systems
for delivery and imaging applications.Conclusions and outlook
Despite the fact that targeted SPIONs have great potential for
theranostics of cancer and possess an acceptable safety margin
for clinical applications, except for most attractive cancer types,
only a few SPION based platforms have been fabricated.
Furthermore, possibly the whole field of targeted imaging and
detection suffers from the lack of very specific and versatile
tumor markers and also targeting moieties that can recognize
such targets. Most tumor markers currently such as FR andintegrins are unspecifically overexpressed by a diverse panel of
tumors. Small antibody fragments such as ScFvs can be valuable
functional targeting ligands for fabrication of NP-based imaging
systems with regard to highest specificity and relatively small
size, however, the complexity of fabrication and potentially the
difficulty in obtaining approval from regulatory agencies can
hinder their clinical applications. Researchers should also make
comprehensive progress toward removing adverse effects of
protein corona in cancer targeting. More specifically, the
personalized protein corona should be considered in fabrication
of targeted NPs. Since early diagnosis and detection of specific
cancer cells in vivo have great implications in patient treatment
and prognosis, more studies need to be focused on fabrication of
NP-based systems for cancer imaging, while in parallel, cancer
genomic and proteomic screenings can be used for identification
and characterization of specific tumor markers for explicit
differentiation of specific tumor types.
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